Publication | Open Access

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formation

Molecular PharmacologyMedicinal ChemistryBiochemistryMedicineNatural SciencesReceptor Tyrosine KinaseMechanism Of ActionReactive Metabolite FormationTrifluoromethylpyrimidine-based InhibitorsStructure–activity RelationshipsPharmacologyDrug Discovery